Osteoporoz tedavisi alan hastalarda tedaviye uyum düzeyleri ve uyumu etkileyen faktörler

Yıl 2020, Cilt: 10 Sayı: 1, 40 - 45, 24.03.2020

Türkan Paşalı Kilit , Kevser Onbaşı , Filiz Özyiğit

https://doi.org/10.33808/clinexphealthsci.533942

Öz

Amaç: Tedaviye uyumu birçok hastalık durumunda optimal sonuçlara ulaşmada önemli bir faktör olarak kabul edilir. Bu çalışmanın amacı osteoporoz hastalarının uyumunu değerlendirmek ve uyumu etkileyen faktörleri saptamaktır.

Yöntemler: Çalışmaya osteoporozu olan toplam 150 hasta dahil edildi. Demografik veriler, antropometrik ölçümler ve hastaların laboratuar sonuçları kaydedildi. Ayrıca, hastaların medeni halleri, eğitim düzeyleri, gelir durumları, sigara ve alkol tüketim alışkanlıkları, egzersiz düzeyleri, beslenme alışkanlıkları, kırık öyküleri, menopoz yaşları, aldıkları tedaviler, ilaç yan etkileri ve tedaviye uyumları içeren anket soruları, yüz yüze görüşme yöntemi ile soruldu.

Bulgular: Çalışmaya alınan 150 hastanın yaş ortalaması 65,6±9,8 idi. Hastaların %94'ü kadındı. Oral ajanlarla osteoporoz tedavisi alan hastalar, subkutan veya intravenöz ajan alan hastalara göre tedaviye daha düşük uyum göstermişlerdir (p=0.003). Diğer faktörlerin uyum üzerine etkisi yoktu.

Sonuç: Akılcı ilaç kullanımı ilkeleriyle ilgili kavramlardan biri olan tedaviye uyum, tedavi başarısının önemli bir parçasıdır. Osteoporoz tedavisinde subkutan veya intravenöz uygulanan ajanların seçimi, oral ajanlara göre tedaviye daha iyi uyum sağlanmasına neden olacaktır.

Anahtar Kelimeler

Osteoporoz, tedavi uyumu, oral ilaç uygulaması, subkutan enjeksiyonlar, intravenöz enjeksiyonlar

Treatment Adherence Levels and Factors Affecting Adherence in Patients Receiving Osteoporosis Treatment

Öz

Objective: Treatment adherence is regarded as an important factor in achieving optimal outcomes across many disease states. The purpose of this study was to evaluate the adherence of osteoporosis patients and determinate the factors affecting adherence.

Methods: A total number of 150 patients with osteoporosis were included in the study. Demographic data, anthropometric measurements and laboratory results of the patients were recorded. In addition, the survey questions including patients' marital status, education levels, income status, smoking and alcohol consumption habits, exercise levels, dietary habits, fracture histories, menopausal ages, treatments they received, medication side effects and treatment adherences were asked by a face-to-face interview method.

Results: The mean age of the 150 patients included in the study was 65.6±9.8 years. Ninety-four percent of the patients were female. Patients who received osteoporosis treatment with oral agents had poorer adherence to treatment than patients receiving subcutaneous or intravenous agents (p=0.003). Other factors had no effect on adherence.

Conclusion: Treatment adherence, which is one of the concepts related to the principles of rational drug use, is an important part of treatment success. The choice of agents administered subcutaneously or intravenously in the treatment of osteoporosis will result in better adherence with treatment than oral agents.

Anahtar Kelimeler

Osteoporosis, adherence, bisphosphonate

Kaynakça

• Referans1 Toklu HZ, Akıcı A, Keyer Uysal M, Ayanoğlu Dülger G. The role of the doctor and pharmacist in improving patient adherence in the process of rational drug use. Turkish Journal of Family Practice 2010; 14: 139-45.
• Referans2 Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am 2013; 44: 125-35.
• Referans3 Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014; 142: 155-70.
• Referans4 Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, et al.; Turkish Osteoporosis Society. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int 2012; 23: 949-55.
• Referans5 Khan AA, Hanley DA, Bilezikian JP, Binkley N, Brown JP, Hodsman AB, et al.; Canadian Panel of the International Society for Clinical Densitometry. Standards for performing DXA in individuals with secondary causes of osteoporosis. J Clin Densitom 2006; 9: 47-57.
• Referans6 Alejandro P, Constantinescu F. A Review of Osteoporosis in the Older Adult: An Update. Rheum Dis Clin North Am 2018; 44: 437-51.
• Referans7 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
• Referans8 Mosekilde L, Vestergaard P, Rejnmark L. The pathogenesis, treatment and prevention of osteoporosis in men. Drugs 2013; 73: 15-29.
• Referans9 McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48: 271-87.
• Referans10 Sahni S, Tucker KL, Kiel DP, Quach L, Casey VA, Hannan MT. Milk and yogurt consumption are linked with higher bone mineral density but not with hip fracture: the Framingham Offspring Study. Arch Osteoporos 2013; 8: 119.
• Referans11 Jaramillo JD, Wilson C, Stinson DS, Lynch DA, Bowler RP, Lutz S, et al.; COPDGene Investigators. Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. Ann Am Thorac Soc 2015; 12: 648-56.
• Referans12 Borer KT. Physical activity in the prevention and amelioration of osteoporosis in women :interaction of mechanical, hormonal and dietary factors. Sports Med 2005; 35: 779-830.
• Referans13 Yağmur Y. Genç kadınlara uygulanan osteoporozdan korunmaya yönelik sağlığı geliştirme programının etkinliğinin değerlendirilmesi. İnönü Üniversitesi Tıp Fakültesi Dergisi 2006; 134: 257-62.
• Referans14 Kılıç D, Erci B. Premenopozal dönemdeki kadınlara verilen eğitimin osteoporoza ilişkin sağlık inançları ve bilgi düzeylerine etkisi. Atatürk Üniversitesi Hemşirelik Yüksekokulu Dergisi 2007; 10: 34-44.
• Referans15 Üstündağ N, Korkmaz M, Öksüzkaya A, Balbaloğlu Ö, Karataş Eray İ. Classification of Osteoporosis, Determining Risk Factors and One Minute Osteoporosis Risk Test. Eurasian Journal of Family Medicine 2013; 2: 107-14.
• Referans16 Gonnelli S, Masi L, Brandi ML, Nuti R. Implementing adherence to osteoporosis treatments. Clin Cases Miner Bone Metab 2009; 6: 193-6.
• Referans17 Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med 2011; 78: 39-49.
• Referans18 Castelo-Branco C, Cortés X, Ferrer M; UNICAD study investigators. Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric 2010; 13: 578-84.
• Referans19 Vytrisalova M, Blazkova S, Palicka V, Vlcek J, Cejkova M, Hala T, et al. Self-reported compliance with osteoporosis medication-qualitative aspects and correlates. Maturitas 2008; 60: 223-9.
• Referans20 Gokce Kutsal Y, Barak A, Atalay A, Baydar T, Kucukoglu S, Tuncer T, et al. Polypharmacy in the elderly: a multicenter study. J Am Med Dir Assoc 2009; 10: 486-90.
• Referans21 Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150: 841-5.Referans22 Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother 2005; 39: 319-28.
• Referans23 Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18: 1023-31.
• Referans24 Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 2414-9.
• Referans25 Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28: 236-42.